Billionaire David Einhorn’s 10 Stock Picks with Huge Upside Potential

1. Roivant Sciences Ltd. (NASDAQ:ROIV)

Greenlight Capital’s Q4 Stake: $62.3 million

Analyst Upside as of April 30: 291.59%

Number of Hedge Fund Holders: 44

Roivant Sciences Ltd. (NASDAQ:ROIV) is a commercial-stage biopharmaceutical company that is dedicated to developing and commercializing treatments for inflammation and immunology.

On April 22, H.C. Wainwright reaffirmed Roivant Sciences Ltd. (NASDAQ:ROIV)’s Buy rating and $18 price target. The company’s management structure recently experienced substantial changes, coinciding with Roivant’s decision to include Sjögren’s disease (SJD) and cutaneous lupus erythematosus (CLE) as the fifth and sixth indications for its investigative medication, IMVT-1402.

Roivant Sciences Ltd. (NASDAQ:ROIV) published earnings for the third quarter of 2024 on February 10, which came above analysts’ expectations. The company’s net income was $118.1 million, compared to $5.1 billion in the same period last year. The drop was primarily due to the absence of a gain on the sale of Telavant net assets, which contributed considerably to the previous year’s revenue. Revenue for the quarter was $9.0 million, a decrease from $15.6 million in the prior year. Operating expenses also rose to $283.4 million from $236.5 million, owing to increasing R&D and general and administrative costs.

Tourlite Capital Management, an investment management firm, released a Q4 2024 investor letter. Here is what the fund said:

“We continue to believe Roivant Sciences Ltd. (NASDAQ:ROIV) offers an attractive risk reward and multiple ways to win. Excluding Roivant’s cash balance and Immunovant (IMVT) stake, the remainder of Roivant (ROIV stub) is valued at less than $2 per share. We believe Roivant’s stake in Arbutus and its exposure to the LNP litigation could alone be worth up to $4. In addition to ROIV, we remain shareholders in Arbutus.”

While we acknowledge the potential for ROIV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%.  If you are looking for an AI stock that is more promising than ROIV but trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks to Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.